Back to Search
Start Over
Efficacy of bisphosphonates in specific knee osteoarthritis subpopulations: protocol for an OA Trial Bank systematic review and individual patient data meta-analysis.
- Source :
-
BMJ open [BMJ Open] 2018 Dec 19; Vol. 8 (12), pp. e023889. Date of Electronic Publication: 2018 Dec 19. - Publication Year :
- 2018
-
Abstract
- Introduction: Randomised clinical trials to date investigating the efficacy of bisphosphonates in knee osteoarthritis (OA) have found divergent results, with a recent meta-analysis finding no superiority of these drugs over placebo. Whether particular patient subgroups are more likely to benefit from this therapy than others is still unclear. We aim to investigate the effects of bisphosphonates compared with a control group (placebo, no treatment, another active treatment) on clinical and structural outcomes in specific knee OA subpopulations with possible distinct rates of subchondral bone turnover.<br />Methods and Analysis: Medline, Embase, Scopus, Web of Sciences and Cochrane Central Register of Controlled Trials will be searched from inception to February 2018. Randomised clinical trials will be eligible if they reported at least one potential treatment effect modifier at baseline: gender, menopausal status, age, body mass index, radiographic stage, knee pain severity, presence of bone marrow lesions, levels of biochemical markers of bone turnover (serum and/or urinary) and systemic bone mineral density status. Authors of original trials will be contacted to obtain individual patient data from each study. Risk of bias will be assessed using the Cochrane Collaboration's tool. The primary outcomes will include pain and radiographic joint space width loss. Studies using other MRI-based assessment of disease progression will also be eligible. Outcomes will be grouped into short-term (≤3 months), intermediate-term (>3 months; ≤12 months) and long-term (>12 months). Regression models will be used, adding an interaction term for each subgroup of interest to determine possible subgroup effects. There was no source of funding for this study.<br />Ethics and Dissemination: Dissemination of our findings is planned to occur through conference presentations, publication in peer-reviewed journals and social media. No formal ethics approval is generally required as no new data collection will be undertaken.<br />Prospero Registration Number: CRD42018093327.<br />Competing Interests: Competing interests: Professor David Hunter reports personal fees from consulting fees from Merck Serono, Flexion and Tissuegene, outside the submitted work. Prof. Bierma-Zeinstra reports grants from the European Union, The Netherlands Organisation for Health Research and Development, Dutch Arthritis Foundation, CZ, Nuts Ohra, Stichting Coolsingel, personal fees from Infirst Healthcare and from Osteoarthritis and Cartilage, outside the submitted work. All other authors have nothing to disclose.<br /> (© Author(s) (or their employer(s)) 2018. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.)
- Subjects :
- Aged
Female
Humans
Male
Middle Aged
Absorptiometry, Photon methods
Age Factors
Bone Density drug effects
Dose-Response Relationship, Drug
Drug Administration Schedule
Prognosis
Randomized Controlled Trials as Topic
Range of Motion, Articular physiology
Risk Assessment
Severity of Illness Index
Sex Factors
Treatment Outcome
United States
Meta-Analysis as Topic
Classification
Diphosphonates adverse effects
Diphosphonates therapeutic use
Osteoarthritis, Knee diagnostic imaging
Osteoarthritis, Knee drug therapy
Pain Measurement drug effects
Subjects
Details
- Language :
- English
- ISSN :
- 2044-6055
- Volume :
- 8
- Issue :
- 12
- Database :
- MEDLINE
- Journal :
- BMJ open
- Publication Type :
- Academic Journal
- Accession number :
- 30573485
- Full Text :
- https://doi.org/10.1136/bmjopen-2018-023889